How Supplied and Stored
		How Supplied Each dose of Kineret® is supplied in a 1 mL prefilled glass syringe, containing 0.67 mL (100 mg) of anakinra.1,2 Each syringe is accompanied by a 27 gauge needle.3 Kineret® is distributed in a dispensing pack containing 4 boxes, each box containing 7 syringes and 7 needles, for a total of 28 available subcutaneous injections per pack4. Storage Kineret® must not be used beyond the expiration date printed on the carton. Each dose of Kineret® should be inspected before administration. The solution in the syringe should be free from all particulate matter and not display any discoloration. If particulates or discoloration are observed, the prefilled syringe should not be used.6 Kineret® should never be shaken or allowed to freeze. If a syringe is left at room temperature for longer than 24 hours, it should be discarded. Kineret® should be stored in a refrigerator and kept at 36° to 46°F (at 2° to 8°C). Kineret® should be protected from prolonged exposure to light.7,8 Formulation Each dose of Kineret® is supplied as a preservative-free, sterile, clear, colorless-to-white solution contained in a prefilled glass syringe. Each prefilled syringe consists of 0.67 mL (100 mg) of anakinra in a solution (pH 6.5), which contains 1.29 mg of sodium citrate, 5.48 mg sodium chloride, 0.12 mg disodium EDTA, and 0.70 mg polysorbate 80 in Water for Injection, USP.9 References   1 Kineret® (anakinra) Prescribing Information. 2 Kineret® (anakinra) Information for Patients and Caregivers:2. 3 Kineret® (anakinra) Prescribing Information. 4 Kineret® (anakinra) Prescribing Information. 6 Kineret® (anakinra) Prescribing Information. 7 Kineret® (anakinra) Prescribing Information. 8 Kineret® (anakinra) Information for Patients and Caregivers:2. 9 Kineret® (anakinra) Prescribing Information.   ABOUT KINERET® ABOUT IL-1 PROFESSIONAL RESOURCES REIMBURSEMENT IMPORTANT PRODUCT SAFETY INFORMATION GLOSSARY
	Kineret® (anakinra) is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease-modifying antirheumatic drugs (DMARDs). Kineret® can be used alone or in combination with DMARDs other than tumor necrosis factor (TNF) blocking agents. In clinical trials, there was a risk of serious infections (2% in Kineret® patients vs. less than 1% in placebo patients). Kineret® should be discontinued if a patient develops an infection, however most patients can continue taking Kineret® after their infection resolves. Kineret® should not be used with TNF-blocking agents such as etanercept, adalimumab, and infliximab. A 7% rate of serious infections was observed in a 24-week study of concurrent administration of Kineret® and etanercept. Kineret® is contraindicated in patients with known hypersensitivity to E coli-derived proteins, Kineret®, or any components of the product. The most common side effect in clinical trials was injection site reaction, which was usually mild and characterized by redness, swelling, and pain. Biovitrum.com | Site Map © 2008 Biovitrum Ab (publ). All rights reserved. This site is intended for U.S. audiences only.